BCL2L1 and diffuse large B-cell lymphoma: Concurrent continuous exposure to AZD4573 and BET bromodomain inhibitor JQ1 fully abrogated MYC, BCL2L1, and IRF8 mRNA transcription in DLBCL cells (Fig. 4C).